aap Implantate

Rubino Di Girolamo will relinquish his position as chairman of the management board/CEO and his board mandate by mutual agreement with the supervisory board as of 31 December 2026. The supervisory board has with immediate effect appointed Cornelius Fink as a management board member and head of the Trauma business unit, and Nicole Kassel as a management board member and CFO. » Más en de.investing.com

The management board of aap Implantate has resolved a cash capital increase of 788,150 new bearer shares at an issue price of EUR 1.34 per share, representing about 5% of the share capital. The shares will be issued as a private placement to selected investors without subscription rights and will be entitled to profits from 1 January 2025. The gross proceeds amount to EUR 1,056,121 and will be used to strengthen the equity base. » Más en finanzen.net